MAPT and Alzheimer disease: Additionally, Slaets et al. [41] reported that the addition of CSF Aβ1‐42/1‐40 to a biomarker panel for AD diagnosis consisting of Aβ1‐42, Aβ1‐40 and tau phosphorylated at threonine 181 (p‐tau181) significantly improved diagnostic accuracy compared with the same panel without Aβ1‐40 and Aβ1‐42/1‐40.